Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome

Archives of Gynecology and Obstetrics

Volumn 293, Issue 5, 2016, Pages 1101-1106

  Şahin, Nur ^a   Apaydın, Nesin ^b   Töz, Emrah ^b   Sivrikoz, Oya Nermin ^a   Genç, Mine ^a   Turan, Gülüzar Arzu ^a   Cengiz, Hakan ^a   Eskicioğlu, Fatma ^c  

^a SIFA UNIVERSITY   (Turkey)

^b Allergology and Clinical Immunology Unit   (Turkey)

^c Manisa Hospital   (Turkey)

Author keywords

Cabergoline; Letrozole; Ovarian hyperstimulation syndrome; Pigment epithelium derived growth factor; Vascular endothelial growth factor

Indexed keywords

CABERGOLINE; CHORIONIC GONADOTROPIN; GONADOTROPIN; LETROZOLE; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; VASCULOTROPIN; ERGOLINE DERIVATIVE; EYE PROTEIN; NERVE GROWTH FACTOR; NITRILE; PIGMENT EPITHELIUM-DERIVED FACTOR; SERIC GONADOTROPIN; SERINE PROTEINASE INHIBITOR; TRIAZOLE DERIVATIVE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; NONHUMAN; OVARIAN DIAMETER; OVARY HYPERSTIMULATION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RAT; SINGLE DRUG DOSE; TISSUE LEVEL; UROGENITAL SYSTEM PARAMETERS; WISTAR RAT; ANIMAL; BLOOD; CAPILLARY PERMEABILITY; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; HUMAN; METABOLISM; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; PREGNANCY;

ANIMALS; CAPILLARY PERMEABILITY; CHORIONIC GONADOTROPIN; ERGOLINES; EYE PROTEINS; FEMALE; GONADOTROPINS, EQUINE; HUMANS; NERVE GROWTH FACTORS; NITRILES; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; PREGNANCY; PROSPECTIVE STUDIES; RATS; RATS, WISTAR; SERPINS; TRIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84963730447     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3987-4     Document Type: Article

References (29)

1. Klemetti R, Sevon T, Gissler M, Hemminki M (2005) Complications of IVF and ovulation induction. Hum Reprod 20(12):3293–3300
2. Stewart JA, Hamilton PJ, Murdoch AP (1997) Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 12(10):2167–2173
3. McClure N, Healy DL, Rogers PA et al (1994) Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344:235–236
4. Pietrowski D, Szabo L, Sator M et al (2012) Ovarian hyperstimulation syndrome is correlated with a reduction of soluble VEGF receptor protein level and a higher amount of VEGF-A. Hum Reprod 27:196–199
5. Carizza C, Abdelmassih V, Abdelmassih S et al (2008) Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 17:751–755
6. Liu X, Chen HH, Zhang LW (2013) Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy. Int J Ophthalmol 6(2):221–227
7. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY (2004) Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 101(17):6605–6610
8. Yamagishi S, Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, Okuda S (2007) Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 14(8):832–835
9. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Shimizu K, Takegami Y, Shimizu T, Inoue H, Imaizumi T (2006) Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res 71(3):222–226
10. Saylan A, Arioz DT, Koken T et al (2010) Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Acta Obstet Gynecol Scand 89:692–699
11. Tong XM, Zhang SY, Song T et al (2008) Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. Chin Med J (Engl) 121:2434–2439
12. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC et al (2006) Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability with-out altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147:5400–5411
13. Alvarez C, Marti-Bonmati L, Novella-Maestre E et al (2007) Dopamine agonist capergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931–2937
14. Quintana R, Kopcow L, Marconi G et al (2008) Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil Steril 90:1511–1516
15. Hong T, Cheng S (2006) Aromatase inhibitors: structural features and biochemical characterization. Ann N Y Acad Sci 1089:237–251
16. Delvigne A (2009) Symposium: update on prediction and management of OHSS. Epidemiology of OHSS. Reprod Biomed Online 19(1):8–13 (review)
17. Hong Y, Chen S (2006) Aromatase inhibitors: structural features and biochemical characterization. Ann N Y Acad Sci 1089:237–251 (review)
18. He Qiaohua, Liang Linlin, Zhang Cuilian, Li Hangsheng, Zhaojia Ge Lu, Wang Shihong Cui (2014) Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval. Syst Biol Reprod Med 60(6):355–360
19. Wang YQ, Yang J, Xu WM, Xie QZ, Yan WJ, Yin TL, Cheng D, Xiao ZN, Li J (2013) Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome. Beijing Da Xue Xue Bao 45(6):869–872
20. Kumar P, Sait SF, Sharma A, Kumar M (2011) Ovarian hyperstimulation syndrome. J Hum Reprod Sci 4(2):70–75
21. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A (2008) Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 14(4):321–333
22. Chuderland D, Hasky N, Ben-Ami I, Kaplan-Kraicer R, Grossman H, Shalgi R (2013) A physiological approach for treating endometriosis by recombinant pigment epithelium-derived factor (PEDF). Hum Reprod 28(6):1626–1634
23. Busso CE, Garcia-Velasco J, Gomez R et al (2009) Symposium: update on prediction and management of OHSS. Prevention of OHSS–dopamine agonists. Reprod Biomed Online 19:43–51
24. Amir H, Yaniv D, Hasson J, Amit A, Gordon D, Azem F (2015) Cabergoline for reducing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial. J Reprod Med 60(1–2):48–54
25. Kasum M, Vrčić H, Stanić P, Ježek D, Orešković S, Beketić-Orešković L, Pekez M (2014) Dopamine agonists in prevention of ovarian hyperstimulation syndrome. Gynecol Endocrinol 5:1–5
26. Papanikolaou EG, Polyzos NP, Humaidan P, Pados G, Bosch E, Tournaye H, Tarlatzis B (2011) Aromatase inhibitors in stimulated IVF cycles. Reprod Biol Endocrinol 21(9):85
27. Garcia-Velasco JA, Quea G, Piro M et al (2009) Letrozle administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril 92:222–225
28. Ceyhan ST, Onguru O, Fidan U, Ide T, Yaman H, Kilic S, Baser I (2011) Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model. Eur J Obstet Gynecol Reprod Biol 154(1):100–104
29. Ferrero H, García-Pascual CM, Morales C, Simón C, Gaytán F, Pellicer A, Gómez R (2014) Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. Fertil Steril 102(5):1468–1476